

**Title:** Changes in life expectancy and life span equality during the COVID-19 epidemic

in Japan up to 2022.

**Article type:** Original Article

**Authors:**

Yuta Okada<sup>a</sup>, Hiroshi Nishiura<sup>a</sup>

<sup>a</sup> Graduate School of Medicine, Kyoto University, Kyoto 6068503, Japan

**Correspondence to:** Hiroshi Nishiura

**Address:** Kyoto University, Yoshidakonoecho, Sakyo, Kyoto city, Kyoto 6068503,

Japan

**Tel:** +81-75-753-4456; **Fax:** +81-75-753-4458

**Email:** [nishiura.hiroshi.5r@kyoto-u.ac.jp](mailto:nishiura.hiroshi.5r@kyoto-u.ac.jp)

## Abstract

Demographic analyses enable the evaluation of the impact of COVID-19 on life expectancy. We evaluated the relationship between the life expectancy change from 2020–21 and 2021–22 and COVID-19 epidemic size at prefectural level in Japan. We also conducted age- and cause-specific decomposition of life expectancy change. Trends in life span equality from 2000–22 were evaluated at the national level. Prefectural analysis of 2021–22 life expectancy change and annual per-population COVID-19 cases, person-days in intensive care, and reported COVID-19 deaths showed no significant correlations, unlike our analysis from 2020–21. However, decomposition analysis revealed substantial life expectancy shortening attributable to the population over 35 years old. It also showed large increases in causes of death such as cardiovascular or respiratory disorders as well as COVID-19. Whole-population life span equality declined in 2020 but increased in 2021 and 2022 despite the shorter life expectancy. The discrepancy between life expectancy change and COVID-19 statistics in 2022 suggests the growing ascertainment bias of COVID-19. The increased contribution of cardiovascular disorders to life expectancy shortening is an alarming sign for the future. Life span equality changes in 2021 and 2022 can probably be attributed to increased mortality among older people.

34

35 **Keywords:** COVID-19; life expectancy; excess mortality; Arriaga Method; life span  
36 equality; Japan

## 37 **Introduction**

38 Since the start of the COVID-19 pandemic in Wuhan, China in November 2019,  
39 evidence of the pandemic's impact on mortality has accumulated globally, with  
40 substantial geographical heterogeneity.<sup>1–6</sup> Global studies suggest that from January 1<sup>st</sup>,  
41 2020 to December 31<sup>st</sup>, 2021, excess deaths worldwide were in the range of 14.9–15.9  
42 million, with a large proportion attributed to India and the United States.<sup>3,4</sup> Published  
43 studies suggest that the global life expectancy change was –1.6 years from 2019 to  
44 2021, when many countries showed bounce-backs from the shortening in 2020.  
45 However, other countries faced sustained shortening into 2021.<sup>4–6</sup>

46 It is now several years since the emergence of COVID-19, and the evaluation of the  
47 mortality impact of the condition has become more difficult for several reasons. One  
48 reason is changes in the official COVID-19 statistics, which are provided by public  
49 health agencies around the world and reflect epidemic activity. These are now less  
50 rigorous than in 2020, because most countries have gradually diminished their effort

either to control the spread of COVID-19 or to maintain a meticulous surveillance system. Another reason is the change in the nature of deaths associated with COVID-19 since the introduction of vaccines against the disease in late 2020. The direct mortality impact of COVID-19 has been alleviated by these vaccines, but a substantial proportion of deaths are caused indirectly through complications such as cardiovascular disorders, or by limited access to healthcare services when the healthcare capacity or ambulance system were overwhelmed by the increased case load pressure of COVID-19.<sup>5,7-15</sup> The ongoing emergence of SARS-CoV-2 variants with a high capability of immune evasion and transmission may have worsened the health impact of COVID-19, but understanding the true burden has remained a challenging task.<sup>16,17</sup>

Direct approaches to estimating the mortality impact of COVID-19 are therefore challenging, including in Japan. There, the epidemic size of COVID-19 was greatest upon the emergence of SARS-CoV-2 Omicron (B.1.1.529) lineage variants. In line with other regions, Japan has been severely affected by COVID-19 in terms of excess mortality and life expectancy shortening.<sup>1,3-5,14,18-21</sup> The updated estimates by the National Institute of Population and Social Security Research suggest that life expectancy at birth has shortened for two consecutive years, from 84.58 years in 2021 to 84.10 in 2022 for the total population. However, it is not clear whether the cause-

specific impact of this shortening has changed since 2021. It is also not clear how the contribution of cardiovascular, respiratory, and neoplastic disorders in 2021 have changed.<sup>18</sup> From a demographic perspective, the change in life span equality during and since the COVID-19 pandemic is also interesting. One measure of life span equality, or, evenness of life span, is the logarithm of the inverse of life table entropy. Global and historical demographic analysis suggests that the trends in life expectancy at birth and life span equality have been in line with each other.<sup>22,23</sup> However, this might not be the case when the age–mortality structure changes drastically. For example, during the COVID-19 epidemic in Japan, the mortality increase in 2021 contributed substantially to shorter life expectancy.<sup>18</sup>

To examine the demographic impact of the COVID-19 epidemic in 2022 in Japan, we investigated the relationship between reported COVID-19 burden at the prefectural level and life expectancy. We also decomposed the year-on-year life expectancy change from 2019–22 by age groups and major causes of death, and evaluated the lifetime loss by age and life span equality during the COVID-19 epidemic.

## Results

The life expectancy at birth in Japan for the total, male, and female populations from 2019–2022 is shown in Supplementary Table 1. These results were based on abridged life tables that we re-calculated for use in Arriaga decomposition, but which are almost identical to results provided by JMD. The life expectancy of the total population decreased by 0.49 years, from 84.59 to 84.10 from 2021–22. A decrease in life expectancy was also seen from 2020–21 of 0.15 years (from 84.74 to 84.59 years). However, the magnitude of the shortening was greater in 2021–22. The shortening of life expectancy at birth for both male and female populations also increased from 2021–22, by 0.43 years for men (from 81.49 to 81.06 years) and 0.50 years for women (from 87.62 to 87.12 years).

Figure 1 shows life expectancy changes in the total population by prefecture in 2019–20, 2020–21, and 2021–22. Following the drastic change from an overall increasing trend in 2019–20 to a sharply decreasing trend in 2020–21, all but one prefecture saw a decline in life expectancy from 2021–22. In 2022, the greatest decrease in life expectancy was seen in Iwate (1.00 years), and the only prefecture where life expectancy continued to increase was Nagasaki (0.05 years). The prefecture-level life

expectancy changes of the male and female populations were largely consistent with that for the total population (for the details, see Supplementary Data).

Figure 2 shows the correlation between reported COVID-19 burden and life expectancy changes at the prefectural level. Combined with the linear regression results shown in Table 1, there was no obvious correlation between annual reported cases, person-days in intensive care, and death due to COVID-19 in 2021–22. However, this was contrary to the findings from 2020–21.

Figure 3 shows the results of the Arriaga decomposition of life expectancy change by age groups and major causes of death. An aggregated summary by age groups and causes of death is shown in Supplementary Figures 1 and 2. There was a clear negative contribution among the older population in 2020–21, and this negative contribution was even bigger in 2021–22. The age range of the group contributing to the reduction also widened in 2021–22 to as low as 30–34 years.

Figure 3 also shows the contributions of major causes of death by age groups. The negative contribution of COVID-19 among the older population expanded substantially in 2021–22. The total contribution by all ages grew from –0.095 years in 2020–21 to –0.131 years in 2021–22. In addition to COVID-19, the negative contribution of cardiovascular causes also grew considerably in 2021–22, especially

among those over 50 years old. The total contribution of cardiovascular death was  $-0.091$  years in 2022, which was a consistent and substantial reduction compared with  $+0.073$  years in 2020 and  $-0.003$  years in 2021. The negative contribution of “other” causes (the remaining causes of death beyond the top nine major categories) also increased substantially in 2021–22 among the population over 50 years old, with a total of  $-0.139$  years across all age groups. There was a clear decrease in the contribution of respiratory and neoplastic disorders, and other causes from 2020–21 to 2021–22 (see Supplementary Data for detailed results). Results from the decomposition analysis for the male and female populations were similar to that of the total population (Supplementary Data and Supplementary Figures 3 and 4).

The values of  $h(t)$  as an indicator of life span equality for the total population from 2000 to 2022 are shown in Figure 4. Panel (A) shows that  $h$  largely increased consistently up to 2019, except in 2011 when an exceptional number of casualties occurred due to the earthquake and tsunami that hit eastern Japan. That increasing trend was halted in 2020 when the COVID-19 pandemic started, but has resumed since 2021. The values of  $h(t)$  for the female and male populations showed very similar patterns to those for the total population (Supplementary Figures 5 and 6). Panel (B) in Figure 4 shows the relationship between  $h(t)$  and life expectancy at birth from 2000 to 2022. A



decrease in  $h(t)$  was seen in 2020 for the first time since 2011, and was followed by an increase in 2021 and 2022 despite the shortening of life expectancy at birth.

To see how the overall dynamics of  $h(t)$  from 2020 to 2022 can be explained by mortality improvements by age for this period (in relation to  $a^H$ ), we calculated curves of  $w(x, t)W_h(x, t)$  across ages for 2021 and 2022. (Figure 5A) We also evaluated the year-on-year mortality improvement  $r(x, t)$  from 2020 to 2022 for the total population (Figure B). As in panel A of Figure 5, the curves of  $w(x, t)W_h(x, t)$  for 2021 and 2022 for the total population were very similar, although there was a slight shift toward the younger ages in the negative part of the curve for the older population. As for  $r(x, t)$ ,  $r(x, 2020)$  above  $x = a^H$  lay in the positive range, whereas  $r(x, 2021)$  and  $r(x, 2022)$  mostly lay in the negative range for the age range as seen in panel B of Figure 5. For ages younger than  $x = a^H$ , the signs of  $r(x, 2020)$ ,  $r(x, 2021)$ , and  $r(x, 2022)$  were inconsistent across different ages, suggesting that increased mortality among those older than  $a^H$  clearly contributed to the increase of  $h(t)$  in 2021 and 2022 (see Supplementary Figures 6 and 7 for results on the female and male populations).

## 153 Discussion

154 Our study showed the pattern of deaths in Japan during the COVID-19  
155 epidemic (up to 2022) through demographic information. The main finding was the  
156 growing impact of the older population and cardiovascular deaths on the shortening of  
157 life expectancy, which was considerable from 2021 to 2022. The lack of significant  
158 correlations between life expectancy change and epidemiological indicators of the  
159 COVID-19 burden from 2022 is also a concern. This finding may be linked to the low  
160 detection of COVID-19 cases and associated deaths, which is supported by our results  
161 about the age- and cause-specific contributions to life expectancy change. The  
162 increasing trend in life span equality despite the life expectancy shortening may also be  
163 related to the substantial increase in mortality among the older population.

164 There were two key findings from our study. The first was that all age groups  
165 over 30 years old contributed to the shortening of life expectancy in 2022, as shown in  
166 Figure 3 and Supplementary Figure 1. However, compared with the overall shortening  
167 attributed to age groups over 50 in 2021, the negative impact was more diffuse across  
168 ages. This finding is similar to what was observed in 2020–21 in countries in Eastern  
169 Europe, though the underlying situations in these countries, such as types of circulating  
170 SARS-CoV-2 variants, vaccine coverage, and healthcare situations, would have been

quite different from that in Japan from 2021–22.<sup>5</sup> In Japan, the population-wide vaccine coverage of the second dose of mRNA vaccines (BNT162b2 [Pfizer/BioNTech] and mRNA-1273 [Moderna] vaccines) was around 80% by the end of 2021, and the coverage of the third dose also increased from around 15% at the end of 2021 to 68% by the end of 2022.<sup>24</sup> Despite this high vaccination rate, we found substantial mortality caused by COVID-19 in Japan among wider age groups in 2022. This was not fully captured by COVID-19 statistics, as seen in our prefectural analyses (Figure 2 and Table 1).

Another key finding was the substantial growth in the negative contribution of cardiovascular disorders to life expectancy shortening, especially among populations over 50 years old (Figure 3 and Supplementary Figure 2). This was not surprising, because published studies have shown an elevated risk of cardiovascular diseases associated with COVID-19.<sup>12–14,25</sup> However, to our knowledge, our study is the first to have quantified the magnitude of life expectancy shortening in Japan caused by cardiovascular deaths in 2022. The negative change in contributions by respiratory causes from 2021 to 2022 and the consistently negative trend in contributions by neoplastic disorders since 2020 are also of note. In addition to COVID-19-associated conditions, these findings may be attributable to an array of factors including changes in

hospital attendance.<sup>18</sup> There is a gap between these findings and the global and regional cause-specific contributions to life expectancy change from 2019–21.<sup>26</sup> Further update on this issue is warranted to evaluate changes in life expectancy change by causes of death. The increase in the contribution of remaining causes of death is mostly explained by the increase in deaths due to senility, which increased by around 20,000 in 2021 and 27,000 in 2022.<sup>27</sup>

The changes in life span equality during the COVID-19 pandemic were also of note. Our result highlights the undesirable increase in life span equality despite the shortening of life expectancy at birth. This was in line with the substantial negative contribution by the older population to life expectancy changes in the same period, highlighted by the Arriaga decomposition results. These findings add to demographic case studies on the historical relationship between life expectancy and life span equality.<sup>22,23</sup>

Our study had some limitations. First, we could not examine the relationship between COVID-19 and other causes of death in detail at the prefectural level, because data on prefectural death count stratified by age and cause of death are not openly accessible. Detailed analysis of prefectural data would have provided insights on geographic heterogeneity, and we hope to explore this in future. Second, we ignored

207 geographic and temporal variation in the ascertainment bias for COVID-19 statistics.

208 We sufficiently met our key focus to be confident about the true mortality burden of

209 COVID-19, but these factors could have biased our analysis of the relationship between

210 prefectural COVID-19 statistics and life expectancy change. Third, we did not consider

211 the fluctuation in the coverage of death registrations in Japan from 2019–22. However,

212 it is unlikely that we missed a large proportion of deaths that would substantially affect

213 our results, because the completeness of death registration is reported to be 90–99% in

214 Japan.<sup>28</sup>

215 In conclusion, our demographic analysis showed the impact of the COVID-19

216 epidemic up to 2022, when the epidemic grew substantially larger. The demographic

217 burden of the pandemic increased more in 2022 than in 2021 or before, but the COVID-

218 19 burden reported by epidemiological surveillance failed to capture this trend. This is

219 probably due to both the shrinking coverage of epidemiological surveillance and the

220 growing impact of COVID-19-associated deaths caused by complications such as

221 cardiovascular disorders. We also showed an undesirable increase in life span equality

222 due to disproportionately higher mortality among older people. Our study therefore

223 provides valuable insights into the mortality impact of the COVID-19 epidemic in

224 Japan, which can now only be captured by indirect measures such as demographic

225 analysis in the absence of meticulous epidemiological surveillance.

## 226 **Methods**

### 227 **Epidemiological data**

228 We used the data on deaths and exposure-to-risk populations available in the  
229 Japanese Mortality Database (JMD), which was available for the whole of Japan and by  
230 prefecture.<sup>29</sup> Death counts by cause of death and age group were obtained from the vital  
231 statistics published by the Ministry of Health, Labour and Welfare of Japan.<sup>30</sup> In line  
232 with a previous study, we categorized major causes of death using the International  
233 Statistical Classification of Diseases and Related Health Problems 10<sup>th</sup> Revision (ICD-  
234 10) into the top nine major cause categories (based on death counts by cause in 2022),  
235 and aggregated the remainder into a single group, to give a total of ten groups.<sup>18</sup> The  
236 epidemiological data for COVID-19 were retrieved from the open-access data provided  
237 by the Ministry of Health, Labour and Welfare.<sup>31</sup>

### 238 **Calculation of period life table**

239 For subsequent use for age- and cause-specific decomposition of life expectancy  
240 gaps, we re-calculated period life tables from 2000 to 2022 for the whole of Japan and

for all prefectures as described before.<sup>18,27</sup> We obtained age group-specific mortality  $m_x$  using death counts and exposure-to-risk population in each age group  $x$ . Using  $m_x$  and  $a_x$ , the average length of time to death in deceased individuals in age group  $x$ , we calculated  $q_x$ , the probability of death in age group  $x$  as:

$$q_x = \begin{cases} \frac{m_x w_x}{1 + (w_x - a_x) m_x}, & x = 0, 1-4, 5-9, \dots 95-99, \\ 1, & x = 100+, \end{cases}$$

where  $w_x$  is the time interval of age group  $x$ . Starting from an initial population

$$l_0 = 100,000,$$

$l_x$  can be obtained by iteratively applying the formula:

$$l_{x+1} = l_x(1 - q_x),$$

for age groups  $x = 0, 1-4, 5-9, \dots 100+$  (in years). Using  $l_x$  and  $a_x$  values,

$$L_x = w_x l_{x+1} + a_x d_x = w_x l_{x+1} + a_x l_x q_x,$$

$$T_x = \sum_{i=x}^{100+} L_i,$$

where  $L_x$  is the person-years spent in age group  $x$ ,  $d_x = l_x q_x$  is the number of deaths in age group  $x$ , and  $T_x$  is the person-years of life remaining for those in age group  $x$ . The life expectancy of age group  $x$ ,  $e_x$ , is then calculated as:

$$e_x = \frac{T_x}{l_x},$$

and the life expectancy at birth is calculated as  $e_0 = T_0/l_0$ .

## Life expectancy change and COVID-19 statistics at the prefectural level

Three COVID-19 statistics at prefectural level were used for this analysis: (i) annual number of COVID-19 cases, (ii) annual number of person-days in intensive care because of COVID-19, and (iii) annual number of documented deaths due to COVID-19. Using each of the COVID-19 indicators as an explanatory variable, we used linear regression analysis to predict the year-on-year life expectancy change as the dependent variable for 2020–21 and 2021–22.

## Decomposition of annual life expectancy change by age and cause of death

In line with a recent study, we used the Arriaga method for age- and cause-specific decomposition of life expectancy change.<sup>18,32,33</sup> The total contribution of age group  $x$  to the life expectancy change (in years) from year  $y$  to year  $y + 1$ , denoted as  $C_x$ , can be described as:

$$C_x = \left[ \frac{l_x^y}{l_0} \left( \frac{L_x^{y+1}}{l_x^{y+1}} - \frac{L_x^y}{l_x^y} \right) \right] + \left[ \frac{T_{x+1}^{y+1}}{l_0} \left( \frac{l_x^y}{l_x^{y+1}} - \frac{l_{x+1}^y}{l_{x+1}^{y+1}} \right) \right]. \quad (1)$$

We then decomposed  $C_x$  into cause-specific contributions:

$$C_x^i = C_x \left[ \frac{R_x^{i,y+1} m_x^{y+1} - R_x^{i,y} m_x^y}{m_x^{y+1} - m_x^y} \right], \quad (2)$$



where  $C_x^i$  is the contribution of cause of death  $i$  in age group  $x$ ,  $R_x^i$  is the proportion of deaths in age group  $x$  associated with cause  $i$ , and  $m_x$  is the overall mortality rate in age group  $x$ .

## Life span equality $h$

We used a measure of life span equality  $h$ , which was derived from life table entropy  $\bar{H}$ .<sup>22,34–36</sup> Life table entropy  $\bar{H}(t)$  is a measure of variation, or inequality, in life span at time  $t$  that is defined as:

$$\bar{H}(t) = -\frac{\int_0^\infty l(x, t) \ln(l(x, t)) dx}{\int_0^\infty l(x, t) dx} = \frac{e^\dagger(0, t)}{e_0(t)},$$

where  $e^\dagger(0, t)$  is the special case of:

$$e^\dagger(x, t) = -\frac{\int_x^\infty l(a, t) \ln(l(a, t)) da}{l(x, t)} = \frac{\int_x^\infty d(x, t) e(x, t) dx}{l(x, t)},$$

which is the life disparity, or the life expectancy loss after birth, and  $e_0$  is the life expectancy at birth. Using  $\bar{H}(t)$ , life span equality  $h(t)$  is defined as:

$$h(t) = -\log(\bar{H}(t)).$$

Note that, contrary to  $\bar{H}(t)$ , the value of  $h(t)$  is the measure of life span equality. We used a 1×1 year life table provided by JMD to calculate  $h(t)$  from 2000 to 2022 for

288 total, male, and female populations, and evaluated the relationship between  $h(t)$  and

289 life expectancy at birth,  $e_0(t)$ , for each of these populations.<sup>29</sup>

290 Aburto et al.<sup>22</sup> described the variation of  $h(t)$  over time as:

$$291 \quad \frac{\partial h}{\partial t} = -\frac{\frac{\partial \bar{H}}{\partial t}}{\bar{H}} = \int_0^\infty w(x, t) W_h(x, t) \rho(x, t) dx,$$

292 where

$$293 \quad \rho(x, t) = -\frac{\frac{\partial \mu(x, t)}{\partial t}}{\mu(x, t)} = -\frac{\partial}{\partial t} \log(\mu(x, t))$$

294 is the mortality improvement in age  $x$  over time,

$$295 \quad w(x, t) = \mu(x, t) l(x, t) e(x, t) = d(x, t) e(x, t)$$

296 is the weight of the contribution of  $\rho(x, t)$  to life expectancy change in age  $x$ , and

$$297 \quad W_h(x, t) = \frac{1}{e_0} - \frac{1}{e^+(0, t)} (H(x, t) + \bar{H}(x, t) - 1)$$

$$298 \quad = \frac{1}{e_0} - \frac{1}{e^+(0, t)} \left( \int_0^x \mu(x, t) dx + \frac{e^+(x, t)}{e(x, t)} - 1 \right).$$

299 Thus,  $w(x, t) W_h(x, t)$  can be considered as the weight, or sensitivity, of  $h(t)$  to  $\rho(x, t)$

300 at age  $x$ . We calculated  $w(x, t) W_h(x, t)$  and the threshold age  $a^H$  that satisfies

301  $W_h(a^H, t) = 0$  for  $t = 2000, 2001, \dots, 2022$ . These results were compared with year-

302 on-year mortality improvement, i.e.,  $r(x, t) = \log(\mu(a, t)) - \log(\mu(a, t + 1))$ , which

is analogous to  $\rho(x, t)$  as described above. We calculated the values such as  $h(t)$ ,  $\bar{H}(t)$ , and  $a^H$  in a discretized manner regarding ages, which has been previously described elsewhere.<sup>22,35</sup>

## Software

All analyses used R version 4.2.2.<sup>37</sup>

## References

1. Bilal, U. *et al.* Life expectancy and mortality in 363 cities of Latin America. *Nature Medicine* 2021 27:3 **27**, 463–470 (2021).
2. Wang, H. *et al.* Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. *Lancet* **399**, 1513–1536 (2022).
3. Msemburi, W. *et al.* The WHO estimates of excess mortality associated with the COVID-19 pandemic. *Nature* 2022 613:7942 **613**, 130–137 (2022).
4. Schumacher, A. E. *et al.* Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *The Lancet* **0**, (2024).
5. Schöley, J. *et al.* Life expectancy changes since COVID-19. *Nature Human Behaviour* 2022 6:12 **6**, 1649–1659 (2022).
6. Aburto, J. M. *et al.* Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries. *Int J Epidemiol* **51**, 63–74 (2022).
7. Watson, O. J. *et al.* Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* **22**, 1293–1302 (2022).
8. Link-Gelles, R. *et al.* Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. *JAMA Netw Open* **6**, e232598–e232598 (2023).

- 332 9. Rossman, H. *et al.* Hospital load and increased COVID-19 related mortality in  
333 Israel. *Nature Communications* 2021 12:1 **12**, 1–7 (2021).
- 334 10. Hayashi, K. & Nishiura, H. Time-dependent risk of COVID-19 death with  
335 overwhelmed health-care capacity in Japan, 2020–2022. *BMC Infect Dis* **22**, 1–  
336 10 (2022).
- 337 11. French, G. *et al.* Impact of Hospital Strain on Excess Deaths During the COVID-  
338 19 Pandemic — United States, July 2020–July 2021. *MMWR Morb Mortal Wkly*  
339 *Rep* **70**, 1613–1616 (2021).
- 340 12. Knight, R. *et al.* Association of COVID-19 With Major Arterial and Venous  
341 Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in  
342 England and Wales. *Circulation* **146**, 892–906 (2022).
- 343 13. Raisi-Estabragh, Z. *et al.* Cardiovascular disease and mortality sequelae of  
344 COVID-19 in the UK Biobank. *Heart* **109**, 119–126 (2023).
- 345 14. Lee, W. E. *et al.* Direct and indirect mortality impacts of the COVID-19  
346 pandemic in the United States, March 1, 2020 to January 1, 2022. *Elife* **12**,  
347 (2023).
- 348 15. Kayano, T. *et al.* Number of averted COVID-19 cases and deaths attributable to  
349 reduced risk in vaccinated individuals in Japan. *Lancet Reg Health West Pac* **28**,  
350 (2022).
- 351 16. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron  
352 (B.1.1.529) Variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- 353 17. Carabelli, A. M. *et al.* SARS-CoV-2 variant biology: immune escape,  
354 transmission and fitness. *Nature Reviews Microbiology* 2023 21:3 **21**, 162–177  
355 (2023).
- 356 18. Munira, M. S., Okada, Y. & Nishiura, H. Life-expectancy changes during the  
357 COVID-19 pandemic from 2019–2021: estimates from Japan, a country with low  
358 pandemic impact. *PeerJ* **11**, e15784 (2023).
- 359 19. Woolf, S. H., Masters, R. K. & Aron, L. Y. Effect of the covid-19 pandemic in  
360 2020 on life expectancy across populations in the USA and other high income  
361 countries: simulations of provisional mortality data. *BMJ* **373**, 1343 (2021).
- 362 20. Nomura, S. *et al.* Excess deaths from COVID-19 in Japan and 47 prefectures  
363 from January through June 2021. *Public Health* **203**, 15–18 (2022).
- 364 21. Excess and Exiguous Deaths Dashboard in Japan. Total Number of Deaths |  
365 [exdeaths-japan.org](https://exdeaths-japan.org). <https://exdeaths-japan.org/en/graph/numberof> (2023).

22. Aburto, J. M., Villavicencio, F., Basellini, U., Kjærgaard, S. & Vaupel, J. W. Dynamics of life expectancy and life span equality. *Proc Natl Acad Sci U S A* **117**, 5250–5259 (2020).
23. Colchero, F. *et al.* The emergence of longevous populations. *Proc Natl Acad Sci U S A* **113**, E7681–E7690 (2016).
24. Cabinet Secretariat of the Japanese Government. COVID-19 Vaccine informations.(in Japanese). <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html> (2024).
25. Burn, E. *et al.* Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. *Lancet Infect Dis* **22**, 1142–1152 (2022).
26. Naghavi, M. *et al.* Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet* **0**, (2024).
27. Okada Y & Nishiura H. Supplementary references for open data used in ‘Changes in life expectancy and life span equality during the COVID-19 epidemic in Japan up to 2022.’ Preprint at (2024).
28. United Nations Statistics Division. Birth and Death Registration Completeness Last update: April 2023. <https://unstats.un.org/unsd/demographic-social/crvs/documents/2023-completeness.xlsx> (2023).
29. National Institute of Population and Social Security Research. The Japanese Mortality Database | National Institute of Population and Social Security Research. <https://www.ipss.go.jp/p-toukei/JMD/index-en.asp> (2023).
30. Ministry of Health Labour and Welfare. Vital Statistics Vital statistics of Japan Final data General mortality | File | Browse Statistics | Portal Site of Official Statistics of Japan. [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle\\_facet=tclass1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0) (2024).
31. Ministry of Health Labour and Welfare. Visualizing the data: information on COVID-19 infections. <https://covid19.mhlw.go.jp/en/> (2023).
32. Arriaga, E. E. Measuring and explaining the change in life expectancies. *Demography* **21**, 83–96 (1984).
33. Arriaga, E. E. Changing Trends in Mortality Decline during the Last Decades. in *Differential Mortality* 105–129 (1989). doi:10.1093/oso/9780198288824.003.0006.

34. Keyfitz, N. Mortality Comparisons; The Male-Female Ratio. 54–76 (1985) doi:10.1007/978-1-4757-1879-9\_3.
35. Aburto, J. M., Alvarez, J. A., Villavicencio, F. & Vaupel, J. W. The threshold age of the lifetable entropy. *Demogr Res* **41**, 83–102 (2019).
36. Demetrius, L. Demographic Parameters and Natural Selection. *Proceedings of the National Academy of Sciences* **71**, 4645–4647 (1974).
37. R Core Team. R: The R Project for Statistical Computing. <https://www.r-project.org/> (2023).

## Acknowledgment

Y.O. received funding from the SECOM Science and Technology Foundation. H.N. received funding from Health and Labour Sciences Research Grants (grant numbers 20CA2024, 21HB1002, 21HA2016, and 23HA2005), the Japan Agency for Medical Research and Development (grant numbers JP23fk0108612 and JP23fk0108685), JSPS KAKENHI (grant numbers 21H03198 and 22K19670), the Environment Research and Technology Development Fund (grant number JPMEERF20S11804) of the Environmental Restoration and Conservation Agency of Japan, Kao Health Science Research, the Daikin GAP Fund of Kyoto University, the Japan Science and Technology Agency SICORP program (grant numbers JPMJSC20U3 and JPMJSC2105), and the RISTEX program for Science, Technology, and Innovation Policy (grant number JPMJRS22B4). We thank Melissa Leffler, MBA, of Edanz (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.

425

## 426 **Author contributions**

427 All authors participated in the study design. Y.O. collected and retrieved the data,  
428 conducted the main analysis, and H.N. validated the analysis. Y.O. wrote the first draft  
429 of the paper and created figures and tables. H.N. edited the earlier versions of the  
430 manuscript. All authors read and approved the final version of the manuscript.

## 431 **Data availability**

432 We used openly accessible COVID-19 statistics from the website of the Ministry of  
433 Health, Labour and Welfare, and life tables and related statistics from the website of  
434 National Institute of Population and Social Security Research. The supplementary files  
435 include the datasets used in this study, and also the results of our numerical analyses.  
436 None of the data used in this study contained personally identifiable information.

437

## 438 **Additional information**

439 **Supplementary Information:** The online version contains supplementary material  
440 available at [doi:xxx](#)

441 **Correspondence:** to Hiroshi Nishiura.

442 **Competing interest:** The authors declare no competing interest.

443     **Ethical declarations:** Ethical approval was not required because none of the data used

444     in this study included any personally identifiable information.

445



**Figure 1. Life expectancy changes from 2019–20, 2020–21, and 2021–22 by prefecture.**

Changes from (A) 2019–20, (B) 2020–21, and (C) 2021–22 are shown. In each panel, bars in blue show positive changes, and red bars show negative changes. Prefectures are shown in ascending order by life expectancy change in 2021–22.

**Figure 2. Correlation between life expectancy changes and COVID-19 burden from official statistics.**

Correlation between life expectancy changes and the reported numbers of (A) annual COVID-19 cases, (B) person-days in intensive care due to COVID-19, and (C) deaths due to COVID-19 are shown. The variables on the x-axis are log-scaled in all panels. In each panel, individual prefectures are shown as black triangles for 2020–21 data, or red dots for 2021–22 data. The horizontal dashed line corresponds to “no year-on-year life expectancy change”.

**Figure 3. Arriaga decomposition of life expectancy change by major cause of death and age group, for the total population of Japan.**

Decomposed contribution by age for (A) 2019–20, (B) 2020–21, (C) 2021–22 are shown in each panel. The key to the colors of bars for each major cause are shown in the panel below the plots. Bars representing major causes with a positive contribution to life expectancy are stacked on the right-hand side, and those making negative contributions are stacked on the left-hand side.

**Figure 4. The trend in life span equality from 2000 to 2022, for the total population of Japan.**

Panel (A) shows the dynamics of life span equality by time from 2000 to 2022. Panel (B) shows the same dynamics in relation to life expectancy for the same period, and the years corresponding to the red dots are noted within the figure.

**Figure 5. Weight of change in life span equality and mortality improvement by age, total population.**

Panel (A) shows the weight  $w(x, t)W_h(x, t)$  for  $t = 2022$  (solid blue line) and  $t = 2021$  (dashed red line). Panel (B) describes the year-on-year mortality improvement  $r(x, t) = \log(\mu(a, t)) - \log(\mu(a, t + 1))$  for  $t = 2020$  (red),  $t = 2021$  (green), and  $t = 2022$  (blue). Vertical dashed lines in both panels represent the threshold age  $a^H = 84.10$  for 2022.


**Table 1. Life expectancy change and COVID-19 statistics: summary of linear regression analysis.**

COVID-19 data (log-scale)	Year	Coefficient (95% CI*)	Intercept (95% CI)
Cases	2020-21	-0.104 (-0.189, -0.018)	-0.655 (-1.086, -0.224)
	2021-22	-0.104 (-0.496, 0.288)	-0.652 (-1.266, -0.037)
Person-days in intensive care	2020-21	-0.082 (-0.144, -0.021)	-0.704 (-1.132, -0.277)
	2021-22	-0.053 (-0.117, 0.011)	-0.879 (-1.353, -0.405)
Death	2020-21	-0.067 (-0.137, -0.002)	-0.789 (-1.464, -0.114)
	2021-22	-0.105 (-0.269, 0.060)	-1.338 (-2.671, -0.057)


\*CI, confidence interval

# Life expectancy changes (years) by prefecture, Total Population


(A) 2019-20




(B) 2020-21




(C) 2021-22




# Life expectancy changes (years) and reported COVID-19 burden by prefecture




(A) 2019-20



(B) 2020-21




(C) 2021-22




Cause of Death

Neoplastic	Respiratory	Nervous	Genitourinary or Renal	Mental
Cardiovascular	External	Digestive	COVID-19	Others

(A) Trend of  $h$ , 2000-22




(B) Life Expectancy at Birth and  $h$ , 2000-22





(A)  $w(x)Wh(x)$ , Total Population



(B) Year-on-year Mortality improvement, Total Population

